Traws Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRAW research report →
Companywww.trawspharma.com
Traws Pharma, Inc. , a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
- CEO
- Iain D. Dukes
- IPO
- 2013
- Employees
- 6
- HQ
- Newtown, PA, US
Price Chart
Valuation
- Market Cap
- $14.81M
- P/E
- -1.18
- P/S
- 0.00
- P/B
- -3.25
- EV/EBITDA
- -0.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 489.90%
- ROIC
- 137635.95%
Growth & Income
- Revenue
- $2.79M · 1134.51%
- Net Income
- $9.17M · 116.77%
- EPS
- $0.83 · 102.36%
- Op Income
- $-17,875,000
- FCF YoY
- 30.28%
Performance & Tape
- 52W High
- $3.27
- 52W Low
- $1.00
- 50D MA
- $1.68
- 200D MA
- $1.89
- Beta
- 1.47
- Avg Volume
- 2.16M
Get TickerSpark's AI analysis on TRAW
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 1,793,187 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Apr 16, 26 | ORBIMED ADVISORS LLC | buy | 597,729 |
| Mar 8, 26 | Parker Charles Nolan | other | 104,544 |
| Dec 12, 25 | Parker Charles Nolan | other | 61,571 |
| Oct 12, 25 | Parker Charles Nolan | other | 32,406 |
| Dec 12, 25 | Parker Charles Nolan | other | 15,393 |
| Jul 3, 25 | Parker Charles Nolan | other | 0 |
| Mar 8, 26 | Clarke Trafford | other | 33,435 |
Our TRAW Coverage
We haven't published any research on TRAW yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TRAW Report →